[PDF][PDF] Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from …
R Pieters, H de Groot-Kruseman… - Journal of …, 2016 - scholarlypublications …
R Pieters, H de Groot-Kruseman, V Van der Velden, M Fiocco, H van den Berg, E De Bont…
Journal of clinical oncology, 2016•scholarlypublications …Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia
Based on Minimal Residual Disease Mo Page 1 JOURNAL OF CLINICAL ONCOLOGY
ORIGINAL REPORT Rob Pieters, Peter Hoogerbrugge, and Gertjan Kaspers, Princess M áxima
Center for Pediatric Oncology, Utrecht; Rob Pieters, Hester de Groot-Kruseman, Marta Fiocco,
and Valerie De Haas, Dutch Childhood Oncology Group, The Hague; Vincent Van der Velden
and Jacques Van Dongen, University Medical Center Rotterdam, Rotterdam; Marta Fiocco …
Based on Minimal Residual Disease Mo Page 1 JOURNAL OF CLINICAL ONCOLOGY
ORIGINAL REPORT Rob Pieters, Peter Hoogerbrugge, and Gertjan Kaspers, Princess M áxima
Center for Pediatric Oncology, Utrecht; Rob Pieters, Hester de Groot-Kruseman, Marta Fiocco,
and Valerie De Haas, Dutch Childhood Oncology Group, The Hague; Vincent Van der Velden
and Jacques Van Dongen, University Medical Center Rotterdam, Rotterdam; Marta Fiocco …
Purpose
Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients. Minimal residual disease (MRD) levels during the first months predict outcome and may select patients for therapy reduction or intensification.
scholarlypublications.universiteitleiden.nl